We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Diabetes & Endocrinology

Diabetes & Endocrinology

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

Testosterone and Weight Loss: Decoding the Link Between Sex Hormones and Cardiovascular Risk in Men with Type 2 Diabetes
Cardiologycardiovascular risktestosterone

Testosterone and Weight Loss: Decoding the Link Between Sex Hormones and Cardiovascular Risk in Men with Type 2 Diabetes

By MedXY|Mar 9, 2026

A longitudinal analysis of the Look AHEAD trial demonstrates that baseline testosterone and weight loss-induced changes in SHBG significantly modulate cardiovascular risk in men with type 2 diabetes, highlighting the critical role of hormon

Transitioning to Tubeless Automated Insulin Delivery: Clinical Insights from the RADIANT Trial and Contemporary Management of Type 1 Diabetes
Clinical Updatesautomated insulin deliveryHbA1c

Transitioning to Tubeless Automated Insulin Delivery: Clinical Insights from the RADIANT Trial and Contemporary Management of Type 1 Diabetes

By MedXY|Mar 9, 2026

This review synthesizes the landmark RADIANT trial findings, demonstrating the efficacy of transitioning patients from multiple daily injections to tubeless automated insulin delivery, while integrating broader evidence on genetic susceptib

24-Weekly vs. 12-Weekly Triptorelin: Clinical Equivalence and Enhanced Adherence in Central Precocious Puberty
Diabetes & Endocrinologycentral precocious pubertyNội Tiết Học Nhi Khoa

24-Weekly vs. 12-Weekly Triptorelin: Clinical Equivalence and Enhanced Adherence in Central Precocious Puberty

By MedXY|Mar 7, 2026

A UK multicentre study demonstrates that 24-weekly Decapeptyl SR is as effective and well-tolerated as the 12-weekly regimen for central precocious puberty, offering improved patient satisfaction and reduced clinical burden.

Deciphering ZnT8A: Why Not All Islet Autoantibodies Predict Type 1 Diabetes Risk
Diabetes & EndocrinologyIslet Autoantibodiestype 1 diabetes

Deciphering ZnT8A: Why Not All Islet Autoantibodies Predict Type 1 Diabetes Risk

By MedXY|Mar 7, 2026

The ENDIA cohort study reveals that persistent single ZnT8 autoantibodies detected only via ELISA after age 4 do not significantly increase Type 1 Diabetes risk, whereas earlier detection across multiple assay formats signals higher progres

Renal Function and Metabolic Risk: Reduced eGFR Does Not Independently Increase DKA Risk in Type 1 Diabetes
Diabetes & Endocrinologychronic kidney diseasediabetic ketoacidosis

Renal Function and Metabolic Risk: Reduced eGFR Does Not Independently Increase DKA Risk in Type 1 Diabetes

By MedXY|Mar 7, 2026

A landmark 35-year analysis of DCCT/EDIC data demonstrates that a reduced estimated glomerular filtration rate (30–90 mL/min/1.73 m2) is not an independent risk factor for diabetic ketoacidosis, providing a clearer safety framework for the

Synergistic Protection: Combining GLP-1 Receptor Agonists with Lifestyle Habits Slashes Cardiovascular Risk in Type 2 Diabetes
Cardiologycardiovascular riskGLP-1 receptor agonists

Synergistic Protection: Combining GLP-1 Receptor Agonists with Lifestyle Habits Slashes Cardiovascular Risk in Type 2 Diabetes

By MedXY|Mar 7, 2026

A massive cohort study of nearly 100,000 veterans reveals that while GLP-1 receptor agonists significantly reduce MACE, the combination with a healthy lifestyle offers a 43% lower risk, emphasizing the need for integrated cardiometabolic ca

Beyond the Binary: The Evolving Consensus on the Spectrum of Primary Aldosteronism and Cardiovascular Risk
Cardiologyatrial fibrillationcardiovascular disease

Beyond the Binary: The Evolving Consensus on the Spectrum of Primary Aldosteronism and Cardiovascular Risk

By MedXY|Mar 7, 2026

Recent data from the ARIC study and emerging expert consensus are redefining primary aldosteronism. Rather than a rare, all-or-nothing condition, it is now viewed as a broad spectrum where even subclinical elevations significantly increase

Beyond Mandatory Resection: Active Surveillance Proves Safe for RAS-Positive Thyroid Nodules
Diabetes & Endocrinologyactive surveillanceendocrinology

Beyond Mandatory Resection: Active Surveillance Proves Safe for RAS-Positive Thyroid Nodules

By MedXY|Mar 6, 2026

A new study suggests that isolated RAS mutations in Bethesda III and IV thyroid nodules do not always require surgery. With a 34% malignancy rate and low growth incidence, active surveillance emerges as a viable, safe alternative for approp

Beyond Haploinsufficiency: How Nonsense-Mediated Decay Escape Redefines MODY Diagnosis and Identifies Novel INS Variants
Diabetes & EndocrinologyMODYMonogenic Diabetes

Beyond Haploinsufficiency: How Nonsense-Mediated Decay Escape Redefines MODY Diagnosis and Identifies Novel INS Variants

By MedXY|Mar 6, 2026

A systematic analysis reveals that the pathogenicity of loss-of-function variants in MODY genes is gene-specific and dependent on nonsense-mediated decay status. Crucially, NMD-escape variants in the INS gene represent a novel, clinically d

Oxygen-Guided Success: A New Frontier in Adrenal Venous Sampling for Primary Aldosteronism
Diabetes & EndocrinologyAdrenal Venous Samplingendocrinology

Oxygen-Guided Success: A New Frontier in Adrenal Venous Sampling for Primary Aldosteronism

By MedXY|Mar 6, 2026

Researchers have discovered that measuring oxygen partial pressure (pO2) can significantly improve the accuracy and speed of Adrenal Venous Sampling, providing a cost-effective tool for diagnosing Primary Aldosteronism.

SGLT2 Inhibitors Reduce Gout-Related Medication Burden in Patients with Type 2 Diabetes
Diabetes & Endocrinologygoutpolypharmacy

SGLT2 Inhibitors Reduce Gout-Related Medication Burden in Patients with Type 2 Diabetes

By MedXY|Mar 6, 2026

A large-scale target trial emulation study demonstrates that SGLT2 inhibitors significantly reduce the initiation of allopurinol and the use of anti-inflammatory medications in patients with comorbid gout and type 2 diabetes, offering a pot

Precision Risk Stratification in Cushing’s Disease: Integrating USP8 Genotype and Tumor Size to Predict Long-Term Recurrence
Diabetes & EndocrinologyCushing's Diseaseピットアリ腺腫

Precision Risk Stratification in Cushing’s Disease: Integrating USP8 Genotype and Tumor Size to Predict Long-Term Recurrence

By MedXY|Mar 6, 2026

An international cohort study demonstrates that combining USP8 genotype with tumor size significantly improves the prediction of recurrence in Cushing’s disease, identifying high-risk patients even among those with low postoperative c

Orforglipron Demonstrates Superior HbA1c Reduction Over Oral Semaglutide in Type 2 Diabetes: Results from the ACHIEVE-3 Trial
Diabetes & EndocrinologyOral Semaglutideorforglipron

Orforglipron Demonstrates Superior HbA1c Reduction Over Oral Semaglutide in Type 2 Diabetes: Results from the ACHIEVE-3 Trial

By MedXY|Mar 6, 2026

The ACHIEVE-3 phase 3 trial demonstrates that orforglipron, a novel non-peptide oral GLP-1 receptor agonist, provides superior glycemic control compared to oral semaglutide in adults with type 2 diabetes, despite a higher frequency of gastr

Insulin Resistance Blunts LVAD-Mediated Myocardial Recovery by Impairing the Pentose Phosphate Pathway
Cardiologyheart failureinsulin resistance

Insulin Resistance Blunts LVAD-Mediated Myocardial Recovery by Impairing the Pentose Phosphate Pathway

By MedXY|Mar 2, 2026

Obesity-induced insulin resistance hinders heart failure recovery post-LVAD by disrupting the pentose phosphate pathway. A new study in Circulation suggests insulin sensitizers could restore cardiac repair mechanisms in obese patients.

Women Achieve Greater Weight Loss With GLP-1 Receptor Agonists: A Comprehensive Meta-Analysis of Treatment Heterogeneity
Diabetes & EndocrinologyGLP-1 receptor agonistsmeta-analysis

Women Achieve Greater Weight Loss With GLP-1 Receptor Agonists: A Comprehensive Meta-Analysis of Treatment Heterogeneity

By MedXY|Mar 2, 2026

A systematic review and meta-analysis of 64 randomized trials reveals that GLP-1 receptor agonists lead to significantly higher weight loss in women (10.9%) compared to men (6.8%), while maintaining consistent efficacy across various ages,

Heart Failure Prevention in Type 2 Diabetes: Comparative Effectiveness of GLP-1 Receptor Agonists vs. SGLT-2 and DPP-4 Inhibitors
Clinical UpdatesGLP-1RAheart failure

Heart Failure Prevention in Type 2 Diabetes: Comparative Effectiveness of GLP-1 Receptor Agonists vs. SGLT-2 and DPP-4 Inhibitors

By MedXY|Mar 2, 2026

A large-scale target trial emulation demonstrates that GLP-1RAs significantly reduce heart failure hospitalization risks compared to DPP-4 inhibitors and provide comparable protection to SGLT-2 inhibitors in routine clinical practice.

Short-Course Romosozumab Followed by Denosumab Is Non-Inferior to Standard 12-Month Regimen for Postmenopausal Osteoporosis
Diabetes & Endocrinologybone mineral densityDenosumab

Short-Course Romosozumab Followed by Denosumab Is Non-Inferior to Standard 12-Month Regimen for Postmenopausal Osteoporosis

By MedXY|Feb 24, 2026

The LIDA trial demonstrates that a 3-month abbreviated course of romosozumab followed by denosumab is non-inferior to the standard 12-month regimen in increasing total hip bone mineral density, potentially reducing treatment costs and injec

Proactive Pharmacist Outreach Slashes Hypoglycemia Risk and Optimizes Prescribing in High-Risk Type 2 Diabetes
Diabetes & Endocrinologyhypoglycemiamedication safety

Proactive Pharmacist Outreach Slashes Hypoglycemia Risk and Optimizes Prescribing in High-Risk Type 2 Diabetes

By MedXY|Feb 23, 2026

This randomized clinical trial demonstrates that proactive pharmacist outreach using evidence-based algorithms significantly improves prescribing safety and reduces emergency hypoglycemia events in high-risk patients with type 2 diabetes wi

Long-Term Benfotiamine Treatment Fails to Improve Diabetic Polyneuropathy: Insights from the BOND Randomized Controlled Trial
Diabetes & Endocrinologyclinical trialtype 2 diabetes

Long-Term Benfotiamine Treatment Fails to Improve Diabetic Polyneuropathy: Insights from the BOND Randomized Controlled Trial

By MedXY|Feb 23, 2026

The 12-month BOND study found that high-dose benfotiamine (600 mg daily) did not significantly improve corneal nerve fiber length or other neurophysiological markers in patients with type 2 diabetes and symptomatic polyneuropathy, despite s

Produce Prescriptions Alone Fail to Improve Diabetes Outcomes: Lessons from a Major Pragmatic Trial
Diabetes & EndocrinologydiabetesFood insecurity

Produce Prescriptions Alone Fail to Improve Diabetes Outcomes: Lessons from a Major Pragmatic Trial

By MedXY|Feb 20, 2026

A large-scale randomized trial reveals that monthly produce subsidies do not significantly improve HbA1c or reduce healthcare utilization in food-insecure diabetes patients, suggesting that ‘Food is Medicine’ initiatives require

Prev
24 / 25
1…22232425
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure

Browse by specialty

Open language-specific specialty feeds and department pages.

news6829 articlesCardiology1403 articlesClinical Updates1315 articlesOncology1176 articlesDiabetes & Endocrinology868 articlesNeurology834 articlesPublic Health605 articlesGastroenterology586 articles
Hematology-Oncology
513 articles
Pediatrics493 articles
Internal Medicine464 articles